Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020

Strong benchmark to competitor CD40 antibodiesLund, Sweden, November 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that its CD40 targeting antibody mitazalimab will be presented at the World Immunotherapy Congress, November 2-6, 2020. The presentation will include new benchmark data demonstrating that mitazalimab has the potential to be best-in-class in the CD40 field. The new preclinical data include analyses of mitazalimab compared with analogues of the CD40 antibodies of key competitors. The comparison demonstrates the potent immune-activating properties and

Interim report January – September 2020

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value rose to SEK 148 per share, compared with SEK 136 per share at the start of the year. This is an increase of 9.8 per cent. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 8.2 per cent. The net asset value was SEK 143 per share at 4 November. (1) · The total return on the Latour share was 39.1 per cent during the period measured against the SIXRX, which rose 8.2 per cent. INDUSTRIAL OPERATIONS The third quarter · The industrial operations' order intake rose 10 per cent to SEK 3,

Moberg Pharma’s nomination committee appointed

STOCKHOLM, November 5[th], 2020 – In accordance with the resolution of the Annual General Meeting on October 30[th], 2019, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group

Introducing KONE Office Flow and innovations for high-rise, making buildings smarter, safer and more adaptable for a changing urban world

KONE Corporation, press release, November 5, 2020  KONE, a global leader in the elevator and escalator industry, today introduces a new solution for offices, high-rise buildings and commercial developments: KONE Office Flow™. It transforms how people can move in a lobby or from floor to floor, combining new connected services for elevators, personalized access management and adaptability over the lifetime of buildings, unlike anything in the industry. KONE Office Flow brings a next generation people flow experience to the office, to meet the evolving needs for smart and sustainable

A Quarter Focusing on Efforts Within New Segments

PowerCell Sweden AB grew its sales from MSEK 15.1 to MSEK 16.6 (+10%) during the third quarter. Operating income before items affecting comparability weakened to MSEK -22.3 (-16.6) due to, among other things, negative currency effects and deliberately increased costs for selling and administration in connection to efforts to grow the business and enter new segments.“The relatively modest increase in sales is linked to the timing of the shipments of the individual orders and is not reflecting the underlying trend line”, Karin Nilsson, acting CEO said.Total sales for the third quarter 2020

Nomination Committee appointed in Instalco AB

In accordance with the principles adopted by the general meeting in Instalco AB held on 7 May 2020, the Nomination Committee shall be comprised of the Chairman of the Board of Directors and three members appointed by the three shareholders with the largest number of votes in the company. If either of the shareholders with the largest number of votes waives their right to appoint a member, the shareholder with the next largest shareholding shall be offered the opportunity to appoint a member.The Nomination Committee ahead of the 2021 AGM comprises the following members:  • Niklas Larsson (

Limited liability companies and co-operatives must submit financial statements to the Finnish Trade Register; even active businesses may risk deregistration

The Finnish Patent and Registration Office (PRH) has this week sent reminder letters to about 1,100 limited liability companies and co-operatives that have not submitted their financial statements for registration within one year from the end of the financial period. The PRH can deregister even an active limited liability company or co-operative if they do not file the financial statements by the date given on the letter.Deregistration means that the business is out of action. All limited liability companies and co-operatives must file their financial statements with the Trade Register

DNB Markets - VEF: Already strong, but more to come

VEF’s holdings delivered another strong quarter with 20% NAV growth. Recent industry deals have shown that investors are increasingly rewarding emerging market fintech, and we highlight that VEF offers unique access to 12 leading VC fintechs (~75% in Latin America). We see several potential near-term NAV catalysts, such as a probable financing round in Creditas (38% of GAV), which could lead to significant growth in the coming year; thus, we have raised our fair value to SEK3.2–4.4 (2.6–4.2).Portfolio highlights in Q3. 1) VEF’s NAV grew 20% QOQ in Q3 (16% in local currencies), driven mainly

Interim Report Third Quarter 2020

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO   STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2020 – 30.09.2020. The report is available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “Despite significant challenges for society and businesses caused by the Covid-19 pandemic, the third quarter offered good progress for our business. We have been very busy executing our ambitious STENOCARE 2.0 strategy and look forward to continuing our progress in the final quarter of the

Lynparza approved in the EU for wider ovarian use

5 November 2020 07:15 GMT Lynparza approved in the EU as 1st-line maintenance treatmentwith bevacizumab for HRD-positive advanced ovarian cancer Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. 17.7 months with bevacizumab alone One in two women with advanced ovarian cancer has an HRD-positive tumour AstraZeneca and MSD's Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive

Changes to Eltel’s segment reporting and in Group Management Team

Eltel will launch a new segment structure in the financial reports starting with the January-March 2021 interim report.The current Power and Communication segments will be replaced by four country segments: Finland, Sweden, Norway and Denmark. All future Power and Communication business in these four Nordic countries will be presented under the new country segments. Current solution unit Smart Grids will be divided into the new country segments and solution unit High Voltage, which conducts most of its business in Poland and Germany, will be presented outside segments in Other. As per 1

Lynparza approved in the EU for prostate cancer

5 November 2020 07:10 GMT Lynparza approved in the EU for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival vs. new hormonal agent treatments in BRCA-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD's Lynparza (olaparib) has been approved in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.

Forxiga approved in the EU for heart failure

5 November 2020 07:05 GMT Forxiga approved in the EU for heart failure Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart failure (HF) is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of blood around

AZN: Year-to-date and Q3 2020 results

AstraZeneca PLC 5 November 2020 07:00 GMT Year-to-date and Q3 2020 results On track to meet full-year guidance; executing the strategy of sustainable growth through innovation In the year to date, AstraZeneca delivered increases in the top line, profit and cash, underpinned by a strategy of sustainable growth through innovation. Total Revenue was in line with expectations and the operating performance continued to improve, with earnings growth in the third quarter reflecting Collaboration Revenue and Other Operating Income and Expense weighted towards the fourth quarter. As a

Interim report January-September 2020

· Profit from property management attributable to parent company shareholders amounted to SEK 3,146m (2,970), corresponding to an increase per share by 6 % to SEK 17.48 (16.50) · Long term net asset value amounted to SEK 362.77 per share (311.10) · Rental income amounted to SEK 6,079m (5,577) · Profit after tax attributable to parent company shareholders amounted to SEK 3,063m (4,473) corresponding to SEK 17.02 per share (24.85) Profit from property management for the period amounted to SEK 3,682m (3,398). Profit from property management attributable to parent company

Q2 Report – 30 September 2020

Flexion continues its strong growth with total revenue up by 168% and gross profit up by 190% resulting in positive adjusted EBITDA[‡ ]on IAP revenue for the first time.July 2020 to September 2020 performance · Total revenue increased by 168% to GBP 6.2m (GBP 2.3m)* · Gross profit increased by 190% to GBP 0.8m (GBP 0.3m) · Adjusted EBITDA[‡] improved by 125% to GBP 0.1m (GBP -0.5m) · Operating result improved by 110% to an operating profit of GBP 0.05m (GBP -0.5m) · Earnings per share amounted to GBP 0.08 pence (GBP -1.14 pence) · Cash amounted to GBP 3.7m (GBP 3.1m)

Biotage AB (publ) Interim report January-September 2020

Strong operating margin with good cost control July - September · Net sales amounted to 262.6 MSEK (282.7), a decrease by 7.1 percent and organically* a decrease by 2.7 percent. · Operating profit amounted to 60.7 MSEK (64.3). · Operating margin amounted to 23.1 percent (22.8). · Result after tax amounted to 37.4 MSEK (66.6). · Earnings per share was 0.57 SEK (1.02) before and after dilution. · The cash flow from operating activities decreased to 73.7 MSEK (79.9). · Net cash* at September 30 amounted to 90.2 MSEK (net debt -69.2). · Cash and cash equivalents

Karnov Group reports third quarter results 2020

Stable quarter, strong resultFINANCIAL HIGHLIGHTS THIRD QUARTER · Net sales up 2% to SEK 193 m (190), organic growth was 3%. · EBITA amounted to SEK 77 m (69) with EBITA margin of 39.9% (36.5%). · Adjusted EBITA increased by 4% to SEK 77 m (74) and adjusted EBITA margin was 39.9% (38.9%). · Net result amounted to SEK 28 m (32). · Earnings per share after dilution amounted to SEK 0.28 (0.33). · Adjusted operating cash flow amounted to SEK -1 m (2). CEO flemming breinholt comments on the quarter: With a steady growth in our online offering and continued focus on

Interim Report January–September 2020

Active in the development of SlakthusområdetIn July, John Mattson took possession of three leasehold properties in Slakthusområdet in the City of Stockholm, which we acquired in May. The leaseholds are in a prime location near the future Metro station entrance in the area, where we plan to drive a detailed development plan for starting the development of new housing and workplaces in 2023. Base and total upgrades for apartments built in the 1950s and 1960s on Lidingö are continuing according to the scope planned and John Mattson is nearing its goal to totally upgrade at least 130

BONESUPPORT HOLDING AB (publ) – Publishes Q3 2020 Interim report

Lund, Sweden, 08:00 am CET, November 5, 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2020. STRONG GROWTH IN NORTH AMERICA. GRADUAL RECOVERY IN EUROW JULY - SEPTEMBER 2020 · Net sales increased by 23 percent and amounted to SEK 48.1 million (39.1). · The North America (NA) segment reported a sales increase of 53 percent. · The Europe & Rest of the World (EUROW) segment reported a 4 percent decline in sales. · The gross margin improved to 91.4 percent

Interim report January-September 2020

A QUARTER THAT KICKED OFF A NEW BUSINESS PLANJuly - September 2020 ·Order bookings amounted to SEK 961 million (1,792) · Income amounted to SEK 1,498 million (1,376) · The operating loss amounted to SEK 79 million (5), of which non-recurring items amounted to a negative SEK 65 million · Cash flow from operating activities amounted to an outflow of SEK 167 million (164) ·  Cash flow for the period amounted to SEK 7 million (0) · The loss for the period amounted to SEK 66 million (27) · New long-term financial targets have been adopted in the new business plan

Eltel Group: Interim report January–September 2020

July–September 2020 · Net sales EUR 226.7 million (281.8). Total growth -19.6% and organic growth[1)] in Power and Communication -12.3% · Operative EBITA[2)] EUR 6.7 million (4.1) and operative EBITA margin 2.9% (1.5) · Items affecting comparability EUR -0.7 million (0.2) include asset held for sale · Operating result (EBIT) EUR 5.8 million (3.9) and EBIT margin 2.6% (1.4) · Net result EUR 3.1 million (-3.9) · Earnings per share EUR 0.02 (-0.03), basic and diluted · Cash flow from operating activities EUR -16.2 million (6.7) January–September 2020 · Net sales

Swedbank Economic Outlook: Autumn darkness surrounds the recovery – but there is scope for growth

The outlook for economic recovery has worsened during the autumn. The increasing spread of the coronavirus is causing a slowdown in the economy. The recovery has been uneven, and many sectors continue to struggle. However, Sweden’s public finances remain strong, which means that continued expansionary fiscal policy and structural reforms are possible, according to the latest Swedbank Economic Outlook.The COVID-19 pandemic continues to determine the course of economic development. Despite a strong recovery during the summer, global GDP is expected to decline by 4 per cent this year. Against

Polygiene AB (publ.) Interim Report July 1–September 30, 2020

Strongest quarter ever, new strong partnership agreements in placeQ3 in brief · The best quarter ever with a net sales of 22.9 (20.5) and with a positive growth by 11.7 % compared to the same period last year. · The operating profit/loss before tax for the period has improved over the previous year and amounted to MSEK 2.4 (2.0). · The gross margin has increased at 70.4 (69.9) %. · The cash flow in the third quarter was positive, MSEK 0.5 (1.8). Events during Q3 2020 (July-September) · Polygiene is overall winner in Scandinavian Outdoor Group (SOG) awards 2020! Each

There are no items matching the current filter
There are no more items matching the current filter
Back to top